ASNC-ACC-Letter-to-Congress_Price-Transparency-Legislation_02-01-2024
In February 2024, ASNC and the American College of Cardiology shared with Senate leaders concerns about the implications of Section 4 of S.3458, the Health Care PRICE Transparency Act 2.0, which posed an unnecessary administrative burden on already strained physician practices and would not have resulted in a patient-centric solution to price transparency. Section 4 would likely have impacted the vast majority of physicians, ranging from small family practices to specialists—all of whom provide imaging services in the office setting.
Resource Type
Health Policy Memos
Related Resources
PET Case: F-18 Flurpiridaz PET MPI in Cardio-Oncology
F-18 Flurpiridaz PET MPI in Cardio-Oncology: Guiding Therapy Decisions in a Patient…
PET Case: Visual Perfusion vs Absolute Blood Flow: Differences in Imaging Agents
Case Summary This case illustrates how the differences in tracer extraction fraction…
ASNC Comments to CMS on 2027 HOPPS Proposed Rule
ASNC_Comments-on-2027-HOPPS-proposed-rule_08-31-2026